GO:0007194 negative regulation of adenylate cyclase activity: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007194 describes any process that stops, prevents, or reduces the frequency, rate or extent of adenylate cyclase activity, the enzyme that converts ATP to cyclic AMP.
• The best-characterized mechanism is inhibitory G protein (Gi/Go) signaling, in which ligand-bound Gi-coupled receptors promote Gαi-mediated inhibition of adenylyl cyclase.
• Receptor systems such as cannabinoid CB1/CB2, mu-opioid, amylin/CGRP, and Mas receptors converge on this term to suppress cAMP production.
• Dysregulation of this process contributes to neuroprotective astrocyte reactivity, metabolic control of brown fat thermogenesis, and nociceptive signaling.
• Key experimental tools include cAMP assays, Gi-protein pertussis toxin sensitivity tests, receptor binding assays, and CRISPR-engineered cell models.
• EDITGENE provides knockout, point-mutation, knock-in, overexpression cell models and CRISPR library screening to dissect this pathway.
Description
GO:0007194, negative regulation of adenylate cyclase activity, is a biological process Gene Ontology term that captures any cellular mechanism that stops, prevents, or reduces the frequency, rate or extent of adenylate cyclase (also called adenylyl cyclase) activity. Because adenylate cyclase synthesizes cyclic AMP (cAMP), one of the most versatile second messengers in eukaryotic cells, negative regulation of this enzyme is a central node for controlling hormone, neurotransmitter, and metabolic signaling. The term is therefore essential for researchers studying G protein-coupled receptor (GPCR) signaling, endocrine feedback, neuronal excitability, and metabolic disease.
negative regulation of adenylate cyclase activity At A Glance
| GO ID | GO:0007194 |
|---|---|
| GO term | negative regulation of adenylate cyclase activity |
| Ontology | biological_process |
| Definition | Any process that stops, prevents, or reduces the frequency, rate or extent of adenylate cyclase activity. |
| Synonyms | adenylate cyclase inhibitor; down regulation of adenylate cyclase activity; down-regulation of adenylate cyclase activity; downregulation of adenylate cyclase activity; inhibition of adenylate cyclase activity; negative regulation of adenylyl cyclase activity |
| Major function | Suppression of cAMP production by inhibiting adenylate cyclase catalytic activity. |
| Key mediators | Gi/Go alpha subunits, Gi-coupled GPCRs, and associated regulatory proteins. |
| Representative receptors | Cannabinoid CB1/CB2, mu-opioid, amylin/CGRP, Mas. |
| Physiological contexts | Neuroprotection, thermogenesis, nociception, hormone feedback. |
What Is GO:0007194?
In practical terms, GO:0007194 refers to the biological processes that inhibit or reduce the catalytic activity of adenylate cyclase enzymes. The QuickGO definition states: any process that stops, prevents, or reduces the frequency, rate or extent of adenylate cyclase activity. This includes direct inhibition of the enzyme by inhibitory G protein alpha subunits (Gαi/Go), receptor-mediated suppression through Gi-coupled receptors, and downstream modulation of cAMP levels by phosphodiesterases and receptor desensitization mechanisms.
Why Is negative regulation of adenylate cyclase activity Important in Cell Biology?
Negative regulation of adenylate cyclase activity is a fundamental brake on cAMP signaling, and its dysregulation is linked to diseases ranging from chronic pain and metabolic disorders to neurodegeneration and cancer. Understanding this process helps researchers interpret how Gi-coupled receptors counteract stimulatory Gs signaling, how drugs such as opioids and cannabinoids produce their effects, and how cells maintain cAMP homeostasis.
• Controls cAMP levels, a master second messenger for metabolism, gene expression, and neuronal signaling.
• Mediates the action of Gi-coupled receptors including opioid, cannabinoid, and somatostatin receptors.
• Contributes to neuroprotective astrocyte reactivity through a molecular switch involving adenylate cyclase inhibition.
• Regulates energy expenditure by suppressing brown fat thermogenesis via CLCF1 signaling.
• Modulates nociceptive processing through mu-opioid receptor signaling.
• Participates in hormone and metabolic feedback, including amylin and CGRP effects on hepatocyte cAMP.
• Involved in Mas receptor signaling through Gαi-adenylate cyclase and ERK1/2 pathways.
• Provides a therapeutic target for pain, obesity, and neurodegenerative conditions.
• Essential for interpreting GPCR pharmacology and drug selectivity.
• Enables mechanistic dissection using CRISPR-engineered cell models.
What Happens During negative regulation of adenylate cyclase activity?
Receptor activation and Gi coupling
In simple terms: A signal molecule binds a receptor that tells the cell to stop making cAMP.
The process typically begins when an agonist binds a Gi-coupled GPCR, such as cannabinoid, mu-opioid, or Mas receptors. This promotes the exchange of GDP for GTP on the Gαi subunit, which then dissociates from Gβγ and directly inhibits adenylate cyclase.
Direct inhibition of adenylate cyclase by Gαi
In simple terms: The inhibitory G protein physically blocks the enzyme that makes cAMP.
GTP-bound Gαi binds to the catalytic core of adenylate cyclase and reduces its ability to convert ATP to cAMP. This inhibition can be reversed by GTP hydrolysis and receptor desensitization, and it is often sensitive to pertussis toxin, which ADP-ribosylates Gαi and prevents receptor coupling.
Modulation by phosphodiesterases and downstream effectors
In simple terms: Other enzymes help break down cAMP, reinforcing the reduction.
In some systems, elevated cAMP levels are only observed when phosphodiesterase activity is inhibited, indicating that negative regulation of adenylate cyclase is integrated with cAMP degradation. Downstream kinases such as ERK1/2 can also participate in feedback regulation of this pathway.
Physiological outcomes of reduced cAMP
In simple terms: Less cAMP changes what the cell does, from firing less to storing more energy.
Reduced cAMP alters protein kinase A activity and downstream targets, influencing neuroprotective astrocyte reactivity, brown fat thermogenesis, and nociceptive signaling. These outcomes highlight the broad physiological importance of GO:0007194.
Key Genes Involved in GO:0007194 negative regulation of adenylate cyclase activity
The following genes and proteins are central to negative regulation of adenylate cyclase activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GNAI1 | Encodes Gαi1 subunit that inhibits adenylate cyclase | Core mediator of GO:0007194 |
| GNAI2 | Encodes Gαi2 subunit; phosphorylated in hepatocyte cAMP regulation | Linked to amylin/CGRP signaling |
| GNAI3 | Encodes Gαi3 subunit | Gi-coupled receptor signaling |
| GNAO1 | Encodes Go alpha subunit | Neuronal inhibition of adenylate cyclase |
| CNR1 | Cannabinoid CB1 receptor coupled to Gi | Cannabinoid signaling |
| CNR2 | Cannabinoid CB2 receptor coupled to Gi | Cannabinoid signaling |
| OPRM1 | Mu-opioid receptor coupled to Gi | Nociception and analgesia |
| ADORA1 | Adenosine A1 receptor coupled to Gi | Inhibitory GPCR signaling |
| ADORA3 | Adenosine A3 receptor coupled to Gi | Inhibitory GPCR signaling |
| SSTR2 | Somatostatin receptor 2 coupled to Gi | Neuroendocrine inhibition |
| DRD2 | Dopamine D2 receptor coupled to Gi | Neuromodulation |
| HRH3 | Histamine H3 receptor coupled to Gi | Presynaptic inhibition |
| CHRM2 | Muscarinic M2 receptor coupled to Gi | Cardiac and neuronal inhibition |
| MAS1 | Mas receptor activates Gαi-adenylate cyclase pathway | Mas receptor signaling |
| CLCF1 | Cytokine that suppresses brown fat thermogenesis | Metabolic regulation |
| ADCY1 | Adenylate cyclase isoform 1, target of inhibition | Enzyme being regulated |
| ADCY5 | Adenylate cyclase isoform 5, target of inhibition | Enzyme being regulated |
| ADCY6 | Adenylate cyclase isoform 6, target of inhibition | Enzyme being regulated |
How Is negative regulation of adenylate cyclase activity Regulated?
Negative regulation of adenylate cyclase activity is itself regulated at multiple levels. Receptor desensitization, GTP hydrolysis by Gαi, and phosphodiesterase activity modulate the duration and magnitude of inhibition. Downstream kinases such as ERK1/2 can feed back on the pathway, as shown for Mas receptor signaling. In addition, cytokine signaling such as CLCF1 can influence cAMP-dependent thermogenesis, linking this process to systemic metabolic control.
negative regulation of adenylate cyclase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GNAI1 | Neurodegeneration, pain | Knockout cell line, cAMP assay |
| OPRM1 | Pain, opioid tolerance | Point-mutation knock-in in neuronal cells |
| CNR1 | Neuropsychiatric disorders | Overexpression in HEK293 cells |
| CLCF1 | Obesity, metabolic syndrome | Knockout brown adipocytes |
| MAS1 | Cardiovascular disease | Knock-in reporter cells |
Neurodegeneration and neuroprotection
A molecular switch for neuroprotective astrocyte reactivity involves adenylate cyclase inhibition, suggesting that GO:0007194 contributes to protecting neurons under stress. Dysregulation of this switch may worsen neurodegeneration.
Pain and opioid signaling
Mu-opioid receptors couple to Gi and inhibit adenylate cyclase, a key mechanism for analgesia. Alterations in this pathway can affect pain sensitivity and opioid responsiveness.
Metabolic disorders
CLCF1 inhibits energy expenditure by suppressing brown fat thermogenesis, a process linked to cAMP regulation. Negative regulation of adenylate cyclase may therefore influence obesity and metabolic disease.
Cardiovascular and hormonal regulation
Amylin and CGRP modulate hepatocyte adenylate cyclase, and Mas receptor signaling through Gαi-adenylate cyclase affects cardiovascular biology. These pathways are relevant to metabolic and cardiovascular disorders.
From negative regulation of adenylate cyclase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GNAI1 mediate adenylate cyclase inhibition? | GNAI1 knockout cell line |
| Does a point mutation in OPRM1 alter Gi coupling? | OPRM1 point-mutation knock-in |
| Can we visualize cAMP changes in live cells? | Knock-in cAMP biosensor |
| Does overexpression of CNR1 enhance inhibition? | CNR1 overexpression cell line |
| Which genes regulate this pathway genome-wide? | CRISPR library screening |
| Can we rescue the phenotype with wild-type gene? | Knock-in rescue model |
How to Study the negative regulation of adenylate cyclase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| cAMP ELISA | Intracellular cAMP concentration | Quantify adenylate cyclase inhibition |
| GTPγS binding | G protein activation | Confirm Gi coupling |
| Pertussis toxin treatment | Gi-dependent inhibition | Distinguish Gi from other pathways |
| Western blot | Protein expression and phosphorylation | Assess Gαi and ERK1/2 |
| CRISPR knockout | Gene function loss | Identify essential mediators |
| RNA-seq | Transcriptional changes | Global effects of pathway modulation |
| Live-cell imaging | Real-time cAMP dynamics | Visualize inhibition kinetics |
cAMP measurement assays
cAMP levels are measured using ELISA, radioimmunoassay, or luminescent biosensors to quantify adenylate cyclase activity and its inhibition.
G protein activation assays
GTPγS binding and pertussis toxin sensitivity tests determine whether inhibition is Gi-mediated.
Receptor binding and signaling
Radioligand binding and downstream kinase assays (e.g., ERK1/2) characterize receptor-mediated inhibition.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens identify genes that regulate negative regulation of adenylate cyclase activity.
How CRISPR Can Be Used to Study GO:0007194 negative regulation of adenylate cyclase activity
Knockout
CRISPR knockout of GNAI1, GNAI2, or GNAI3 can abolish Gi-mediated inhibition of adenylate cyclase, providing causal evidence for their roles.
Point Mutation
Point mutations in receptors such as OPRM1 or CNR1 can disrupt Gi coupling, allowing precise structure-function studies of GO:0007194.
Knock-in
Knock-in of fluorescent cAMP biosensors or tagged Gαi subunits enables real-time monitoring of adenylate cyclase inhibition in live cells.
Overexpression
Overexpression of Gi-coupled receptors or Gαi subunits enhances inhibitory signaling, useful for gain-of-function studies.
How EDITGENE Supports negative regulation of adenylate cyclase activity Research
Researchers studying negative regulation of adenylate cyclase activity-related genes often need to determine whether a candidate gene is causally involved in suppressing cAMP production or is merely correlated with the phenotype. EDITGENE provides the CRISPR tools and cell models required to establish causality and dissect mechanism.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of adenylate cyclase activity research.
Frequently Asked Questions About negative regulation of adenylate cyclase activity
What is GO:0007194?
GO:0007194 is the Gene Ontology term for negative regulation of adenylate cyclase activity, any process that reduces the enzyme's ability to produce cAMP.
What genes are involved in negative regulation of adenylate cyclase activity?
Key genes include GNAI1, GNAI2, GNAI3, GNAO1, CNR1, CNR2, OPRM1, and MAS1, which encode Gi-coupled receptors and G proteins.
How does Gi inhibit adenylate cyclase?
Activated Gαi binds adenylate cyclase and directly reduces its catalytic activity, lowering cAMP levels.
What diseases are linked to this pathway?
It is linked to neurodegeneration, pain, obesity, and cardiovascular disorders.
What is the role of cAMP in this process?
cAMP is the product of adenylate cyclase; negative regulation reduces cAMP production and downstream signaling.
Which receptors couple to Gi to inhibit adenylate cyclase?
Cannabinoid, mu-opioid, adenosine, somatostatin, dopamine D2, and Mas receptors are examples.
How can I study negative regulation of adenylate cyclase activity?
Use cAMP assays, GTPγS binding, pertussis toxin sensitivity, and CRISPR knockout models.
What is the difference between Gs and Gi signaling?
Gs stimulates adenylate cyclase to increase cAMP, while Gi inhibits it to decrease cAMP.
Can CRISPR help study this pathway?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can dissect gene function in this pathway.
Why is this pathway important for drug discovery?
Many drugs target Gi-coupled receptors, and understanding adenylate cyclase inhibition helps predict efficacy and side effects.
Conclusion
GO:0007194, negative regulation of adenylate cyclase activity, is a central biological process that controls cAMP signaling through Gi-coupled receptors and G proteins. Its roles in neuroprotection, pain, metabolism, and cardiovascular function make it a high-value target for basic and translational research. CRISPR-based cell models and screening services from EDITGENE can accelerate mechanistic and therapeutic studies of this pathway.
References
- 1. Cameron EG et al.. 2024. A molecular switch for neuroprotective astrocyte reactivity.. Nature 626(7999):574-582 PMID: 38086421
- 2. Baxter JD et al.. 1979. Hormone receptors.. N Engl J Med 301(21):1149-61 PMID: 226885
- 3. Simonds WF. 1999. G protein regulation of adenylate cyclase.. Trends Pharmacol Sci 20(2):66-73 PMID: 10101967
- 4. Demuth DG et al.. 2006. Cannabinoid signalling.. Life Sci 78(6):549-63 PMID: 16109430
- 5. Herman TF et al.. 2026. Mu Receptors.. PMID: 31855381
- 6. Houslay MD et al.. 1994. Regulation of hepatocyte adenylate cyclase by amylin and CGRP: a single receptor displaying apparent negative cooperatively towards CGRP and simple saturation kinetics for amylin, a requirement for phosphodiesterase inhibition to observe elevated hepatocyte cyclic AMP levels and the phosphorylation of Gi-2.. J Cell Biochem 55 Suppl:66-82 PMID: 7929619
- 7. Yuan Y et al.. 2024. CLCF1 inhibits energy expenditure via suppressing brown fat thermogenesis.. Proc Natl Acad Sci U S A 121(3):e2310711121 PMID: 38190531
- 8. Burghi V et al.. 2019. Participation of Gα(i)-Adenylate Cyclase and ERK1/2 in Mas Receptor Signaling Pathways.. Front Pharmacol 10:146 PMID: 30853914
